Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation.

HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2010) 2.04

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood (2007) 1.43

Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol (2007) 1.05

Bone marrow aspiration technique has deteriorated in recent years. Bone Marrow Transplant (2015) 0.89

Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol (2012) 0.88

Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism. Immunology (2009) 0.86

Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Vet Comp Oncol (2007) 0.79

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL. Bone Marrow Transplant (2014) 0.79

Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments. Front Immunol (2016) 0.78

Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance. Am J Transplant (2008) 0.77

Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunol (2014) 0.77

Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. Bone Marrow Transplant (2014) 0.75

Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation. Clin Exp Immunol (2001) 0.75

Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis? J Clin Immunol (2000) 0.75

Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst (1997) 3.30

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood (2001) 2.99

Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. Cancer Genet Cytogenet (2001) 2.57

Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56

Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol (1988) 2.44

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood (1995) 2.43

Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia (2005) 2.24

Bacterial methylation of chlorinated phenols and guaiacols: formation of veratroles from guaiacols and high-molecular-weight chlorinated lignin. Appl Environ Microbiol (1983) 2.08

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (2000) 2.06

Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet (1991) 2.02

Splenectomy for chronic thrombotic thrombocytopenic purpura. Lancet (1990) 1.98

Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood (1978) 1.96

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood (2001) 1.93

Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts. Blood (1979) 1.88

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood (1999) 1.87

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86

Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant (2004) 1.84

Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood (1996) 1.78

Auer rod-like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature. Int J Lab Hematol (2008) 1.77

A controlled randomized study examining the effects of exercise therapy on patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 1.76

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant (2010) 1.74

Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood (1991) 1.74

Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant (2000) 1.72

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia (2004) 1.71

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia (2013) 1.71

Bacterial o-methylation of chloroguaiacols: effect of substrate concentration, cell density, and growth conditions. Appl Environ Microbiol (1985) 1.66

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia (2011) 1.64

Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards. Bone Marrow Transplant (2011) 1.63

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood (1999) 1.63

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant (2008) 1.61

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant (1999) 1.61

Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58

No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant (2008) 1.56

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54

Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant (1998) 1.47

The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer (2000) 1.46

Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation (2000) 1.45

The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood (1999) 1.42

Diabetes insipidus in a patient with a highly malignant B-cell lymphoma and stomatitis. Exp Clin Endocrinol Diabetes (2000) 1.42

[Complications of anticoagulants. Frequency of fatal bleedings justifies more rigid indications]. Lakartidningen (1995) 1.39

Plasma levels of granulocyte colony-stimulating factor in patients after allogeneic bone marrow transplantation for chronic myeloid leukemia correlate with engraftment of transplanted marrow. Bone Marrow Transplant (1997) 1.38

Safety profile of mycophenolate mofetil. Bone Marrow Transplant (2000) 1.37

Transplantation of peripheral blood progenitor cells from unrelated donors. Transplantation (1998) 1.37

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia (2012) 1.37

Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol (2001) 1.35

Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol (2001) 1.34

Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia (2001) 1.34

Methylation of halogenated phenols and thiophenols by cell extracts of gram-positive and gram-negative bacteria. Appl Environ Microbiol (1988) 1.34

A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood (1994) 1.34

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med (2007) 1.34

Transformations of chloroguaiacols, chloroveratroles, and chlorocatechols by stable consortia of anaerobic bacteria. Appl Environ Microbiol (1987) 1.33

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28

Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J Gastroenterol (2001) 1.28

Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant (2009) 1.28

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant (1998) 1.27

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol (2001) 1.25

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia (2011) 1.24

Bacterial O-methylation of halogen-substituted phenols. Appl Environ Microbiol (1987) 1.24

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia (2012) 1.23

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia (2009) 1.22

Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion (1997) 1.21

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21

Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant (2001) 1.20

Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood (1995) 1.19

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia (2006) 1.18

Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant (2012) 1.17

Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion (2001) 1.17

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood (2001) 1.16

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant (2012) 1.16

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant (2010) 1.14

Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood (2001) 1.13